珀戈莱德治疗对马和小马胰岛素失调的影响,这些马和小马患有垂体中介部分功能障碍
Nicolas C Galinelli1, Nicholas J Bamford1, Madison L Erdody1
1Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.
Equine veterinary journal
|February 19, 2025
概括
珀戈利德在患有胰岛素失调 (ID) 的马匹中没有改善胰岛素敏感性. 然而,它降低了PPID和ID的马的食后胰岛素水平.
科学领域:
- 马类内分泌学 马类内分泌学
- 兽医药理学 兽医药理学 兽医药理学
- 代谢性疾病研究研究.
背景情况:
- 脑下垂体中介性功能障碍 (PPID) 和胰岛素失调 (ID) 在马群中很常见,并与细膜炎有关.
- 多巴胺在胰岛素分泌中的作用需要在这些条件下进一步研究.
研究的目的:
- 为了研究甲基甲酸对胰岛素敏感性和食后胰岛素/葡萄糖反应的影响,在患有ID的马匹中,有或没有PPID.
主要方法:
- 一项随机交叉研究,涉及16匹马/小马 (8匹具有PPID+ID,8只具有ID).
- 马匹接受了pergolide (每天2μg/kg) 或安慰剂4周,有4周的洗期.
- 通过联合葡萄糖-胰岛素耐受性测试 (CGIT) 评估胰岛素敏感性;用标准饮食测试 (SMT) 测量食后反应.
主要成果:
- 珀戈利德在两组中都没有显著改变胰岛素敏感性 (CGIT).
- 在患有PPID+ID的马匹中,百戈利德显著减少了曲线下的食后胰岛素面积和SMT期间的胰岛素度峰值.
- 对于SMT参数,仅在ID组中没有观察到珀戈利德的显著影响.
结论:
- 珀戈利德甲基酸盐不会改善ID的马的组织胰岛素敏感性.
- 这种药物可以帮助马匹同时受到PPID和ID的影响来管理食后胰岛素高血压.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
139
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
139
Parkinson's Disease: Treatment
187
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
187
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
242
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
242
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Heart Failure Drugs: Inotropic Agents
500
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
500
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291


